Skip to main content
Research & Data

TRT Bloodwork Reference Ranges: 4 Labs vs. 3 Guidelines (2026)

By TRT Provider Guide · Last verified: September 2, 2026

Editorial research; not clinically reviewed. This page explains published laboratory ranges and guideline rules. It does not diagnose low testosterone or set a dose.

The number to quote: “A total testosterone result of 280 ng/dL is unflagged at Mayo, Quest, and LabCorp, but low at ARUP. It is also below the AUA’s 300 ng/dL cutoff.”

The finding. Across four major U.S. laboratories checked on September 2, 2026, the adult-male reference range for total testosterone starts anywhere from 240 to 300 ng/dL and ends anywhere from 916 to 1,100 ng/dL. That is a 60 ng/dL spread at the bottom and a 184 ng/dL spread at the top.

In the 10-marker ledger on this page, 4 of 10 markers have at least one numeric decision line in the AUA, Endocrine Society, or EAU guidance: total testosterone, free testosterone, hematocrit, and PSA. Six do not. Free testosterone is the special case: the EAU publishes a number, but free-testosterone methods are not interchangeable, so that number cannot be placed over every lab range as if every test used the same ruler.

For total testosterone, hematocrit, and PSA, at least one guideline decision line sits inside the LabCorp and Quest printed ranges, where the report may show no flag.

The Endocrine Society put the measurement problem plainly on July 16, 2026: the same sample can read “low” or “normal,” depending on the lab and method.

Horizontal chart comparing the adult-male total testosterone reference intervals for Mayo, Quest, LabCorp, and ARUP, with markers at 264, 280, 300, and about 346 ng/dL.

Figure 1. Where 280 ng/dL falls in four published lab intervals. The value is inside the named Mayo, Quest, and LabCorp intervals, below ARUP's 300 ng/dL lower boundary, and below the AUA's 300 ng/dL diagnostic cutoff.

Source: Mayo Clinic Laboratories TGRP; Quest Diagnostics test 15983; LabCorp test 500159; ARUP test 0070109; AUA Testosterone Deficiency Guideline; Endocrine Society 2018 guideline; EAU Male Hypogonadism chapter. Verified September 2, 2026.

Table 1. Adult-male total testosterone reference ranges at four U.S. laboratories, one named test per lab
Laboratory Test and code Method Population behind the displayed range Low end High end
Mayo Clinic Laboratories Testosterone, Total and Free, Serum (TGRP/TTST) LC-MS/MS Men 19 and older; reference values established with morning specimens 240 ng/dL 950 ng/dL
Quest Diagnostics Testosterone, Total, MS (15983) Chromatography/mass spectrometry Adult men 250 ng/dL 1,100 ng/dL
LabCorp Testosterone, Total, Serum, Mass Spectrometry (500159) HPLC/MS-MS; CDC HoSt-certified Men older than 18; interval linked to the harmonized healthy, non-obese 19–39 reference group 264 ng/dL 916 ng/dL
ARUP Laboratories Testosterone, Free and Total, Includes SHBG (0070109) Total testosterone by electrochemiluminescent immunoassay Men 18–39; ARUP lists 300–890 for ages 40–59 and 300–720 for ages 60+ 300 ng/dL 1,080 ng/dL

Source: Mayo Clinic Laboratories TGRP; Quest Diagnostics test 15983; LabCorp test 500159; ARUP test 0070109. Verified September 2, 2026. Computed spreads: 300 − 240 = 60 ng/dL; 1,100 − 916 = 184 ng/dL.

A lab report, a diagnosis rule, a treatment target, and a safety line are four different tools. The rest of this page keeps them apart.

TRT bloodwork reference ranges: why “normal” changes by lab

Answer capsule: A laboratory reference interval describes results for a named test, method, population, and unit. Many two-sided intervals use the central 95% of a reference group, but laboratories can use different procedures. A reference interval is not a treatment target.

The 264–916 ng/dL interval shows why the details matter. The 2017 harmonization study pooled data from 9,054 men across four cohorts. But the 264 and 916 boundaries were derived from a smaller reference sample of 1,185 healthy, non-obese men ages 19–39, after the cohort assays were aligned to the CDC reference method. The 264 and 916 values were the 2.5th and 97.5th percentiles in that reference sample.

LabCorp publishes two total-testosterone tests that share 264–916 ng/dL for most adult ages but use different methods:

  • LabCorp 004226 uses an electrochemiluminescence immunoassay. It lists 150–785 ng/dL at ages 18–19 and 264–916 ng/dL at age 20 and older.
  • LabCorp 500159 lists 264–916 ng/dL and uses HPLC/MS-MS. It is the LabCorp test used in the four-lab boundary comparison above.

Quest also proves why the test code matters. Its mass-spectrometry test 15983 lists 250–1,100 ng/dL. Its adult-male immunoassay panel 30741 lists 250–827 ng/dL. That is a 273 ng/dL difference in the upper boundary inside one company.

Table 2. Four number types that can appear around TRT bloodwork
Number type Plain meaning Example What it does not mean
Lab reference interval The interval a laboratory publishes for one test, method, population, and unit Quest test 15983: 250–1,100 ng/dL One ideal level for every man
Diagnostic cutoff A line used with symptoms, history, and repeat testing AUA: below 300 ng/dL can support diagnosis Everyone below it should start TRT
Treatment target or adjustment band A range used after treatment starts and at a stated draw time AUA: about 450–600 ng/dL; Endocrine Society injection midpoint: adjust outside 350–600 Every point inside the lab interval is equally suitable
Safety or action line A number that triggers review, intervention, or referral AUA: hematocrit 54% or higher warrants intervention Every value just below it is safe for every person

Source: AUA Testosterone Deficiency Guideline; Endocrine Society 2018 guideline; EAU Male Hypogonadism chapter; Travison et al., 2017.

A hematocrit result can be outside a lab interval and still below a guideline action line. A total testosterone result can be inside a lab interval and below a diagnosis cutoff. Neither source is broken. They are answering different questions.

TRT bloodwork reference ranges for 10 common markers

Answer capsule: This ledger compares 10 markers commonly seen in low-testosterone evaluation or TRT monitoring. Four have a numeric decision line in at least one of the three compared guidelines. Six have a lab interval or a use rule, but no shared numeric TRT target in those guidelines.

This is an editorially defined 10-marker ledger, not a claim that every man needs all 10 tests at every visit.

Table 3. The four ledger markers with at least one numeric guideline decision line
Marker LabCorp reference interval shown in this ledger Quest reference interval shown in this ledger Numeric guideline line Direct lab-to-guideline overlay?
Total testosterone Test 500159: 264–916 ng/dL for men older than 18. Test 004226: 150–785 at ages 18–19 and 264–916 at age 20+ 250–1,100 ng/dL on test 15983 AUA: below 300 supports diagnosis; EAU: 12 nmol/L (about 346 ng/dL); Endocrine Society: 264 ng/dL harmonized lower limit on CDC-standardized tests; treatment bands also apply Yes, when the named total-T method and draw conditions are known
Free testosterone Age-banded, 6.6–26.5 pg/mL across adult bands on direct analog test 144980 Calculated panel 30741: 46–224 pg/mL at 18–69 and 6–73 at 70–89; dialysis test 36170 says to use the report EAU 2026: limited evidence supports 220 pmol/L, equal to 6.4 ng/dL or 64 pg/mL No simple overlay across unlike methods
Hematocrit 37.5–51.0% 38.5–50.0% Baseline caution lines around 48–50%; on-treatment management line at 54%, with different instructions by guideline Yes, if baseline and on-treatment rules are kept separate
PSA 0.0–4.0 ng/mL ≤4.0 ng/mL Before treatment: >4.0, or >3.0 in a higher-risk man, needs urologic evaluation under the Endocrine Society guideline; during year one, confirmed rise >1.4 or confirmed PSA >4.0 calls for consultation Yes, but change from baseline matters as much as the absolute value

Source: LabCorp total testosterone 004226, LabCorp total testosterone 500159, LabCorp free testosterone 144980, Quest test 15983, Quest test 30741, Quest test 36170, AUA guideline, Endocrine Society guideline, and EAU 2026 chapter.

Table 4. LabCorp and Quest reference-range ledger for 10 markers, with the guideline role beside each one
# Marker LabCorp adult-male interval and method Quest adult-male interval and method Numeric line in the 3 compared guidelines? What the guidance uses it for
1 Total testosterone Test 004226, ECLIA: 150–785 ng/dL at ages 18–19; 264–916 at age 20+. Test 500159, HPLC/MS-MS: 264–916 for men older than 18. Test 15983: 250–1,100 ng/dL, mass spectrometry. Panel 30741: 250–827 ng/dL, immunoassay. Yes Diagnosis needs symptoms plus repeat morning results. Treatment monitoring uses product-specific timing.
2 Free testosterone Test 144980, direct analog EIA: 9.3–26.5 (20–29), 8.7–25.1 (30–39), 6.8–21.5 (40–49), 7.2–24.0 (50–59), 6.6–18.1 (>59) pg/mL. Test 36170 uses equilibrium dialysis and says to use the report’s age band. Panel 30741 calculated FT: 46–224 (18–69), 6–73 (70–89) pg/mL. Yes, with limits EAU lists 220 pmol/L (64 pg/mL) on limited evidence. Endocrine Society and EAU reject direct FT immunoassays for diagnosis and favor equilibrium dialysis or calculation.
3 SHBG 16.5–55.9 nmol/L (20–49); 19.3–76.4 (>49). Panel 30741: 10–50 nmol/L (18–55); 22–77 (>55). No Helps show when total T may mislead and when calculated free T is useful.
4 Estradiol, sensitive/ultrasensitive Test 140244, LC/MS: 8.0–35.0 pg/mL. Test 30289, LC/MS: ≤29 pg/mL. No AUA uses estradiol in specific settings such as breast symptoms or aromatase-inhibitor treatment; it gives no single TRT target.
5 Hematocrit 37.5–51.0%. 38.5–50.0%. Yes Baseline risk review and on-treatment red-cell safety. The 54% management instructions differ by guideline.
6 Hemoglobin 13.0–17.7 g/dL. 13.2–17.1 g/dL. No Drawn with hematocrit; the compared TRT guidelines write their main numeric action rules for hematocrit.
7 PSA 0.0–4.0 ng/mL. ≤4.0 ng/mL. Yes Baseline prostate-risk assessment and change-from-baseline monitoring.
8 LH 1.7–8.6 mIU/mL. 1.5–9.3 mIU/mL (18–59); 1.6–15.2 (60+). No Helps separate testicular causes from hypothalamic or pituitary causes.
9 FSH 1.5–12.4 mIU/mL. 1.4–12.8 mIU/mL on test 7137. No Helps classify the cause; often most useful when fertility matters.
10 Prolactin 3.6–31.5 ng/mL (13–30); 3.9–22.7 (31–50); 3.6–25.2 (51–80); 3.6–32.0 (>80). 2.0–18.0 ng/mL in Quest’s male-hypogonadism guide. No Used when a pituitary or hypothalamic cause is possible, especially with low or low-normal LH or reduced sexual desire.

Source: LabCorp official pages for 004226, 500159, 144980, 082016, 140244, 004283, 004309, 004465, and 010322; LabCorp hematology interval document; Quest official pages for 15983, 30741, 36170, 30289, 7137, Quest male-hypogonadism guide, and Quest hematology interval notice. Guideline roles: AUA, Endocrine Society, EAU. Verified September 2, 2026.

Counting rule: A marker counts only when at least one compared guideline prints a number used for a diagnosis, treatment, monitoring, safety, or referral decision. A rule such as “check when symptoms appear” does not count unless it includes a number. Under that rule, the count is 4 of 10.

What the data shows—and what it does not

Answer capsule: The report flag and the clinical decision line can disagree because they were made for different jobs. This ledger shows where that happens. It does not tell any one person whether to start, stop, or change treatment.

What the data shows:

  • Total testosterone 280 ng/dL: unflagged at Mayo, Quest test 15983, and LabCorp test 500159; low at ARUP for ages 18–39; below the AUA’s cutoff.
  • Hematocrit 52%: above the LabCorp and Quest intervals. The three compared guideline action rules do not make 52% an automatic stop line. Their 54% instructions differ, and a clinician can act earlier based on the person and the trend.
  • PSA 1.0 to 2.6 ng/mL: both values are inside the two listed lab intervals, but the 1.6 ng/mL increase is greater than the Endocrine Society’s 1.4 ng/mL first-year referral line. The rise should be confirmed before referral.
  • Free testosterone: the same label can describe direct analog EIA, equilibrium dialysis, or a calculated value. The raw numbers are not interchangeable.

What the data does not show:

  • It does not show one “best” testosterone number.
  • It does not show which laboratory is “right.”
  • It does not prove that method alone caused the differences. Age bands and reference groups differ too.
  • It does not replace symptoms, history, repeat testing, dose timing, or a clinician’s judgment.

Methodology: how the 2026 TRT bloodwork dataset was built

Answer capsule: Every source row comes from the issuing laboratory, guideline body, or original study. Derived figures are labeled. We only converted units or subtracted published boundaries, and we show the formula.

Snapshot: September 2, 2026. Dataset version: 1.1.

Source selection

We used:

  1. Official test-directory pages and interval documents from Mayo Clinic Laboratories, Quest Diagnostics, LabCorp, and ARUP Laboratories.
  2. The AUA Testosterone Deficiency Guideline, published in 2018 and validity-confirmed in 2024.
  3. The Endocrine Society’s 2018 clinical practice guideline and July 16, 2026 statement.
  4. The current EAU Male Hypogonadism chapter and its 2026 update page.
  5. The original 2017 harmonization study by Travison and colleagues.

No clinic target, forum post, search-result summary, or third-party range was used as a source cell.

What was recorded

For each ledger row, the downloadable CSV records the marker, organization, test or guideline name, code or section, method, age or population, boundary, unit, clinical role, timing or condition, source URL, verification date, and verification status.

How the headline figures can be reproduced

  • Lowest lower boundary: Mayo, 240 ng/dL.
  • Highest lower boundary: ARUP ages 18–39, 300 ng/dL.
  • Lower-boundary spread: 300 − 240 = 60 ng/dL.
  • Lowest upper boundary: LabCorp test 500159, 916 ng/dL.
  • Highest upper boundary: Quest test 15983, 1,100 ng/dL.
  • Upper-boundary spread: 1,100 − 916 = 184 ng/dL.
  • Quote check for 280 ng/dL: 280 is at or above the Mayo, Quest, and LabCorp lower boundaries; below ARUP’s 300 boundary; and below the AUA’s 300 cutoff.

Unit handling

  • Total testosterone is shown in ng/dL.
  • Mayo free testosterone reported in ng/dL is converted with 1 ng/dL = 10 pg/mL.
  • EAU total testosterone is shown as 12 nmol/L. Using 1 nmol/L = 28.84 ng/dL, that is about 346.1 ng/dL. The EAU page also displays 3.5 ng/mL, equal to 350 ng/dL.
  • EAU free testosterone is shown as 220 pmol/L, which the EAU displays as 6.4 ng/dL; that equals 64 pg/mL.
  • Converted figures are marked “about” or “equal to.” We did not create false precision.

How gaps were computed

Each gap starts at one published boundary and ends at the next. Interval notation keeps the exact rule visible:

  • [264, 300) means 264 is included and 300 is not.
  • (48%, 51%] means greater than 48% through 51%, including 51%.
  • (51%, 54%) means greater than 51% but less than 54%.

Downloads

The CSV files are plain data. Each source row carries a source URL and verification date. Computed rows are marked as computed from verified source values.

Why low-testosterone sources say 264, 300, or about 346 ng/dL

Answer capsule: The numbers do different jobs. The Endocrine Society cites 264 ng/dL as a harmonized lower reference limit for CDC-standardized tests. The AUA uses below 300 ng/dL as a clinical cutoff. The EAU uses 12 nmol/L, about 346 ng/dL, as a diagnostic and potential treatment criterion when symptoms are present.

Table 5. Three total-testosterone lines and how each is used
Line Source What the number is Required context
264 ng/dL (9.2 nmol/L) Endocrine Society 2018, drawing on Travison et al. Harmonized lower reference limit for healthy, non-obese young men on CDC-standardized assays Symptoms or signs plus consistently low results; confirm with repeat fasting morning testing
Below 300 ng/dL AUA A reasonable cutoff in support of diagnosis Symptoms or signs plus two early-morning tests on separate days
12 nmol/L (about 346 ng/dL; EAU also prints 3.5 ng/mL) EAU 2026 Reliable threshold for late-onset hypogonadism and a potential treatment criterion Symptoms plus fasting 07:00–10:00 testing; repeat a low result before treatment

Source: Endocrine Society 2018 guideline; Travison et al., 2017; AUA guideline; EAU 2026 Male Hypogonadism chapter.

The Endocrine Society’s July 16, 2026 statement calls a number near 300 ng/dL the common clinical threshold. That does not erase the 264 ng/dL harmonized lower limit. One is a common clinical decision line; the other is a reference boundary tied to standardized testing.

One repeat test matters because testosterone moves. The Endocrine Society guideline reports that about 30% of men with an initial low result had a normal result when the test was repeated.

Where “normal on the report” disagrees with a guideline

Answer capsule: The clearest gaps are total testosterone below a diagnosis or treatment line, hematocrit between a lab boundary and a management line, and PSA changes that a one-time reference interval cannot see.

Table 6. Eight computed gap zones
Marker Zone LabCorp Quest Mayo ARUP ages 18–39 What the report can show What the guideline adds
Total testosterone Unflagged but below AUA cutoff [264, 300) [250, 300) [240, 300) None No low flag Below 300 can support diagnosis with symptoms and a second early-morning result
Total testosterone Unflagged but below EAU 12 nmol/L line [264, ≈346.1) [250, ≈346.1) [240, ≈346.1) [300, ≈346.1) No low flag EAU uses 12 nmol/L with symptoms and repeat fasting morning testing
Total testosterone On treatment: unflagged but below AUA therapeutic range [264, 450) [250, 450) [240, 450) [300, 450) No low flag AUA defines therapeutic success at about 450–600 ng/dL
Total testosterone On treatment: unflagged but above AUA range and Endocrine Society injection midpoint ceiling (600, 916] (600, 1,100] (600, 950] (600, 1,080] No high flag AUA range ends near 600; Endocrine Society says adjust enanthate/cypionate if the midpoint is above 600
Hematocrit Inside lab interval but above Endocrine Society baseline caution line (48%, 51%] (48%, 50%] — — No high flag Endocrine Society lists >48% as a pre-start risk; EAU says 48–50% needs careful review
Hematocrit High flag but below 54% (51%, 54%) (50%, 54%) — — High flag Below the three guidelines’ 54% management boundary, but still a result that can need review
PSA Inside lab interval but above the higher-risk pre-start line (3.0, 4.0] (3.0, 4.0] — — No high flag Endocrine Society: a higher-risk man needs urologic evaluation before treatment
PSA Confirmed rise >1.4 ng/mL in the first year Any starting value Any starting value — — A static range cannot flag the change Endocrine Society: urologic consultation after the rise is confirmed

Source: Computed by TRT Provider Guide from Tables 1, 3, 5, 7, 9, and 10. Primary inputs: Mayo, Quest 15983, LabCorp 500159, ARUP 0070109, AUA, Endocrine Society, and EAU. Intervals are calculations, not new clinical cutoffs.

The 280 ng/dL example is the cleanest quote because the disagreement is visible without extra math. The PSA rise may be the most important reading lesson: a laboratory can only flag the value against its fixed interval unless a clinician also checks the change from baseline.

What should total and free testosterone look like on TRT?

Answer capsule: No compared guideline gives one perfect number. The AUA uses about 450–600 ng/dL as its therapeutic range. The Endocrine Society aims for the mid-normal range and gives product-specific draw times. Free testosterone must stay tied to its method.

Table 7. Total-testosterone treatment targets and adjustment bands
Guidance Target or adjustment rule When the sample is taken Plain meaning
AUA About 450–600 ng/dL, the middle tertile of the normal physiologic range, using the least dose needed After a formulation-specific interval, then every 6–12 months when stable A narrower treatment range inside many lab intervals
Endocrine Society 2018 Mid-normal range Check 3–6 months after treatment starts, with timing based on product The target is not the full lab interval
Endocrine Society: testosterone enanthate or cypionate Adjust dose or frequency if the midpoint result is >600 or <350 ng/dL Midway between injections The 350–600 band only makes sense at the midpoint
Endocrine Society: injectable testosterone undecanoate Aim for the trough in the low-mid range Just before the next injection A trough is not compared with a midpoint as if they were the same draw

Source: AUA guideline, Statement 22 and follow-up table; Endocrine Society 2018 monitoring table.

A midway enanthate or cypionate result of 620 ng/dL can be inside a laboratory range and above the Endocrine Society adjustment band. Both statements can be true.

Free testosterone: the method comes first

Free testosterone is the small unbound fraction of circulating testosterone. The Endocrine Society recommends checking it when total testosterone is near the lower limit or when a condition may change SHBG. It favors equilibrium dialysis or an accurate calculation using total testosterone, SHBG, and albumin. The EAU also says direct free-testosterone immunoassays should be avoided.

Table 8. Free-testosterone ranges and methods named in this dataset
Laboratory and test Method Age Printed interval Same interval in pg/mL
Mayo TGRP/FRTST Equilibrium dialysis with LC-MS/MS 20 to <25 5.25–20.7 ng/dL 52.5–207 pg/mL
Mayo TGRP/FRTST Equilibrium dialysis with LC-MS/MS 30 to <35 4.85–19.0 ng/dL 48.5–190 pg/mL
Mayo TGRP/FRTST Equilibrium dialysis with LC-MS/MS 40 to <45 4.46–17.1 ng/dL 44.6–171 pg/mL
Mayo TGRP/FRTST Equilibrium dialysis with LC-MS/MS 50 to <55 4.06–15.6 ng/dL 40.6–156 pg/mL
Mayo TGRP/FRTST Equilibrium dialysis with LC-MS/MS 60 to <65 3.67–13.9 ng/dL 36.7–139 pg/mL
Mayo TGRP/FRTST Equilibrium dialysis with LC-MS/MS 70 to <75 3.28–12.2 ng/dL 32.8–122 pg/mL
Mayo TGRP/FRTST Equilibrium dialysis with LC-MS/MS 80 to <85 2.88–10.5 ng/dL 28.8–105 pg/mL
ARUP 2004246 Equilibrium dialysis with mass spectrometry Adult men 47–244 pg/mL 47–244 pg/mL
Quest 36170 Equilibrium dialysis plus total testosterone by mass spectrometry Age-banded See the range on the report —
Quest 30741 Calculated from total T, SHBG, and albumin 18–69 46–224 pg/mL 46–224 pg/mL
Quest 30741 Calculated from total T, SHBG, and albumin 70–89 6–73 pg/mL 6–73 pg/mL
LabCorp 144980 Direct analog EIA 30–39 example 8.7–25.1 pg/mL 8.7–25.1 pg/mL
EAU 2026 decision line Guideline threshold; limited evidence When free T is used to clarify diagnosis 220 pmol/L = 6.4 ng/dL 64 pg/mL

Source: Mayo TGRP; ARUP 2004246; Quest 36170; Quest 30741; LabCorp 144980; EAU 2026 chapter. Mayo conversions use 1 ng/dL = 10 pg/mL.

Do not compare a LabCorp Free, Direct value of 12 pg/mL with a Mayo dialysis value of 120 pg/mL as if one man changed tenfold. They are different measurements with different reference intervals.

What hematocrit level needs action on TRT?

Answer capsule: The laboratory high flag starts at 51.0% for the LabCorp interval and 50.0% for Quest. The three guidelines use 54% as an on-treatment management boundary, but they do not give the same instruction at that boundary.

Hematocrit is the share of blood volume made up of red blood cells. Testosterone can raise it. The baseline rule and the on-treatment rule must not be merged.

Chart separating LabCorp and Quest hematocrit intervals from the Endocrine Society, AUA, and EAU baseline cautions and the 54 percent on-treatment management boundary.

Figure 2. Hematocrit lab flags, baseline cautions, and on-treatment management lines. The rows are separate because these numbers do different jobs and should not be treated as one universal cutoff.

Source: LabCorp hematology intervals; Quest male-hypogonadism guide; Quest hematology interval notice; Endocrine Society guideline; AUA guideline; EAU 2026 guideline. Verified September 2, 2026.

Table 9. Hematocrit numbers by job
Number Job Source What it says
37.5–51.0% Lab reference interval LabCorp Adult-male interval in the cited hematology document
38.5–50.0% Lab reference interval Quest Adult-male interval in the cited Quest document and clinical guide
>48% (>50% at high altitude) Pre-start risk condition Endocrine Society 2018 Listed as a condition with moderate-to-high risk of adverse outcomes
>50% at baseline Pre-start hold/evaluation line AUA Consider withholding therapy until the cause is explained
48–50% at baseline Pre-start caution EAU 2026 Evaluate carefully before treatment, especially when red-cell risk is higher
>54% on treatment Withhold and reassess Endocrine Society 2018 Withhold until it falls, evaluate for hypoxia and sleep apnea, then restart at a lower dose
≥54% on treatment Intervention AUA Intervention is warranted; dose adjustment is first when on-treatment testosterone is high
>54% on treatment Adjust or withdraw EAU 2026 Adjust or withdraw, change formulation, and use venesection if the clinical situation requires it

Source: LabCorp hematology intervals; Quest male-hypogonadism guide; Quest hematology interval notice; Endocrine Society guideline; AUA guideline; EAU 2026 guideline.

When to check it: The Endocrine Society says baseline, 3–6 months, then yearly. The EAU says 3, 6, and 12 months after treatment starts, then yearly. The AUA says to keep hematocrit below 54% and generally checks it every 6–12 months when stable, or sooner based on earlier values.

The AUA notes that injectable testosterone has produced the largest average rises in hemoglobin and hematocrit among formulations in the evidence it reviewed.

The 54% line is a management boundary, not a promise that every result below it is safe or proof that every result above it means the same thing. A rise, symptoms, altitude, smoking, sleep apnea, lung disease, dehydration, and the treatment product can change the clinical picture.

What PSA change matters during TRT?

Answer capsule: A fixed PSA reference interval cannot see a change from baseline. During the first treatment year, the Endocrine Society uses both the absolute value and the confirmed change: a rise greater than 1.4 ng/mL or a confirmed PSA above 4.0 ng/mL calls for urologic consultation.

PSA is made by prostate tissue. A result can rise for more than one reason. The rules below are review and referral rules, not cancer diagnoses.

Table 10. PSA decision numbers in the compared guidance
Number or condition Decision Source Detail
PSA >4.0 ng/mL before treatment Do not start without further urologic evaluation Endocrine Society 2018 Applies before treatment
PSA >3.0 ng/mL before treatment in a higher-risk man Do not start without further urologic evaluation Endocrine Society 2018 The guideline gives African American men and men with a first-degree relative with prostate cancer as higher-risk examples
PSA before treatment in men older than 40 Measure before starting AUA Intended to exclude a prostate-cancer diagnosis before treatment
Confirmed PSA rise >1.4 ng/mL above baseline in first 12 months Urologic consultation Endocrine Society 2018 Repeat the test to confirm a rise before referral
Confirmed PSA >4.0 ng/mL at any time during treatment Urologic consultation Endocrine Society 2018 Confirmation matters because transient rises occur
Prostate abnormality on examination or substantial worsening of urinary symptoms Urologic consultation Endocrine Society 2018 The trigger is not a lab range

Source: Endocrine Society 2018 guideline, recommendations and monitoring table; AUA Testosterone Deficiency Guideline, Statement 12.

Example: PSA goes from 1.0 to 2.6 ng/mL in 10 months. The result is still inside the LabCorp and Quest intervals, but the increase is 1.6 ng/mL. Under the Endocrine Society plan, confirm the rise and use the confirmed change—not the lack of a lab flag—to decide on consultation.

When should TRT bloodwork be drawn?

Answer capsule: Timing is part of the result. Diagnosis tests belong in the morning and usually fasting under the Endocrine Society and EAU guidance. Treatment tests must be timed to the product.

Table 11. Timing before a low-testosterone diagnosis
Guidance Time of day Fasting? Repeat? Other detail
AUA Early morning Not stated as a universal requirement Yes, two tests on separate days Use the same lab and assay when possible
Endocrine Society 2018 Morning Yes Yes Diagnose only with symptoms or signs and consistently low accurate results
EAU 2026 07:00–10:00 Yes Yes after a pathological/low result Nonfasting testing can underestimate total T; night-shift timing should follow sleep pattern

Source: AUA guideline; Endocrine Society 2018 guideline; EAU 2026 chapter.

Table 12. Timing after treatment starts
Product or stage Draw timing How the result is used
Testosterone enanthate or cypionate injection Midway between injections Endocrine Society: adjust dose or frequency if midpoint is >600 or <350 ng/dL
Transdermal gel 2–8 hours after application, after at least 1 week on treatment Adjust toward the mid-normal range
Transdermal patch 3–12 hours after application Adjust toward the mid-normal range
Buccal system Just before or after a fresh system is applied Product-specific interpretation
Pellets At the end of the dosing interval Adjust pellet number or interval to keep the mid-normal range
Injectable testosterone undecanoate Just before the next injection Aim for a trough in the low-mid range
First treatment response check Endocrine Society: 3–6 months. AUA: after an appropriate formulation-specific interval. EAU: first evaluation at 3 months. Check response, adverse effects, testosterone, and the safety labs due at that point
Stable treatment AUA: testosterone every 6–12 months. EAU: testosterone and hematocrit at 3, 6, 12 months, then yearly. Keep the same test and product-timing point when possible

Source: Endocrine Society 2018 monitoring table; AUA follow-up guidance; EAU 2026 monitoring section.

Write four facts beside every on-treatment testosterone result: product, dose, last-dose date and time, and blood-draw date and time. Without them, a midpoint, peak, trough, and random result can look like the same test when they are not.

Which blood tests are core, and which are conditional?

Answer capsule: Total testosterone is the main diagnosis measurement. Hematocrit is a core safety test before and during treatment. PSA monitoring depends on age, risk, and shared decision-making. LH, FSH, prolactin, SHBG, free testosterone, and estradiol answer narrower questions.

Table 13. What each test is for in the compared guidance
Test Main job When the guidance uses it
Total testosterone Main biochemical measurement Repeat morning testing before diagnosis; product-timed monitoring after treatment starts
Hematocrit and hemoglobin Red-cell safety Baseline and follow-up. The main numeric action rules are written for hematocrit.
PSA and prostate examination Prostate-risk assessment AUA: PSA before treatment in men older than 40. Endocrine Society: age- and risk-based monitoring plan, then first-year follow-up when chosen.
LH and FSH Separate testicular from pituitary/hypothalamic causes After low testosterone is confirmed. AUA gives LH a central role; FSH is especially useful when fertility matters.
Prolactin Look for a pituitary cause AUA: low testosterone with low or low-normal LH. EAU: pathologic total T with LH and prolactin; also consider with reduced sexual desire.
Pituitary MRI Look for a pituitary lesion Endocrine Society: severe secondary hypogonadism, persistent high prolactin, other pituitary deficits, or mass symptoms. EAU: headache, visual symptoms, confirmed hyperprolactinemia, and—on limited evidence—TT <6 nmol/L (about 173 ng/dL) with inadequate gonadotropins.
SHBG and free testosterone Clarify a total-T result When total T is near the lower edge or a condition may change SHBG. Use dialysis or a sound calculation, not a direct FT immunoassay for diagnosis.
Estradiol Answer a specific symptom or treatment question AUA: breast symptoms and aromatase-inhibitor use; optional in other settings. No shared numeric TRT target in the three compared guidelines.
Lipid and glycemic profile Metabolic monitoring EAU 2026: baseline, 12 months, then yearly. Other testing follows the person’s conditions and medicines.
Liver and kidney tests General health and product-specific safety No shared numeric TRT target in these three guidelines; order and interpret from the person’s health and current product information.
Bone density Bone health Endocrine Society: after 1–2 years in men with osteoporosis. EAU: consider baseline and 18–24 months, especially in more severe hypogonadism.

Source: Endocrine Society 2018 guideline; AUA Testosterone Deficiency Guideline; EAU 2026 Male Hypogonadism chapter.

Table 14. Short labels used on TRT lab reports
Label Full name Plain job
TT Total testosterone All testosterone measured in the sample
FT Free testosterone The unbound fraction, measured or calculated by a named method
SHBG Sex hormone-binding globulin A carrier protein that changes how total T relates to free T
CBC Complete blood count Includes red cells, hemoglobin, hematocrit, white cells, and platelets
Hct / Hgb Hematocrit / hemoglobin Red-cell volume share / oxygen-carrying red-cell protein
PSA Prostate-specific antigen Prostate marker used with age, risk, examination, and change over time
LH / FSH Luteinizing hormone / follicle-stimulating hormone Pituitary signals to the testes
PRL Prolactin Pituitary hormone that can suppress the reproductive axis when high
E2 Estradiol Estrogen made in part from testosterone
LC-MS/MS Liquid chromatography–tandem mass spectrometry A measurement method used for steroid hormones
ECLIA / EIA Electrochemiluminescence immunoassay / enzyme immunoassay Antibody-based measurement methods
ng/dL, pg/mL, nmol/L, pmol/L Concentration units The unit must stay attached to the value

Source: Terminology and methods as printed in the laboratory directories and guidelines cited throughout this page. Unit conversions used in this ledger are stated in the methodology.

2026 source-status snapshot

Answer capsule: The page uses the current EAU 2026 chapter, the AUA guideline that was validity-confirmed in 2024, and the Endocrine Society’s 2018 guideline read beside its July 16, 2026 statement.

  • EAU: The live Sexual and Reproductive Health guideline is the 2026 update. It uses fasting 07:00–10:00 draws, publishes the 220 pmol/L free-testosterone line with limited evidence, and lays out 3-, 6-, and 12-month monitoring.
  • AUA: The Testosterone Deficiency Guideline was published in 2018 and marked “Reviewed and Validity Confirmed 2024.”
  • Endocrine Society: The detailed clinical practice guideline remains the 2018 guideline. Its July 16, 2026 statement repeats the need for symptoms, two early-morning fasting tests, standardized assays, and ongoing monitoring.

No numeric cell on this page comes from a clinic’s house target.

Limitations

Answer capsule: This is a dated, source-specific ledger for adult men. It is built to make the boundaries visible, not to turn those boundaries into medical advice.

  • Four laboratories, not every laboratory. Hospital systems, regional labs, and home-testing services can publish different intervals.
  • One total-testosterone test per laboratory in Table 1. The exact test code is named. Other tests at the same company can differ.
  • Different age groups and methods. The 60 and 184 ng/dL spreads describe what the four named tests print. They do not prove that one factor caused the full difference.
  • Three guideline bodies, not every professional group. Other organizations may set different rules or focus on different patients.
  • Adult men only. This dataset does not apply its ranges to women or transgender patients.
  • Free testosterone is not harmonized. The EAU number is based on limited evidence, and raw values from unlike methods should not be merged.
  • Reference intervals can change. The test code, method, interval, and verification date belong together.
  • A guideline is not a personal treatment plan. Symptoms, fertility goals, age, other illnesses, medicines, prostate risk, red-cell risk, product, dose, and draw timing can change the decision.
  • Not clinically reviewed. TRT Provider Guide’s editorial team compiled this version from the primary sources below. No clinician reviewed this version.

Frequently asked questions

What is a normal testosterone level on TRT?

There is no single normal number. The AUA uses about 450–600 ng/dL as its therapeutic range. The Endocrine Society says to aim for the mid-normal range and, for testosterone enanthate or cypionate, to adjust when the midway-between-injections result is above 600 or below 350 ng/dL. A lab reference range is wider and has a different job.

Is 300 ng/dL low testosterone?

The AUA says a value below 300 ng/dL can support the diagnosis when symptoms are present and two early-morning tests on separate days agree. Exactly 300 is the boundary, not a result below it. The Endocrine Society cites 264 ng/dL as a harmonized lower reference limit for CDC-standardized tests. The EAU uses 12 nmol/L, about 346 ng/dL, with symptoms and repeat fasting morning testing.

Why does my lab use 264 ng/dL instead of 300?

The numbers came from different processes. The 264 ng/dL value is the 2.5th percentile from 1,185 healthy, non-obese men ages 19–39 after results were harmonized to the CDC reference method. The AUA’s 300 ng/dL number is a clinical cutoff used to support a diagnosis. One is a reference boundary; the other is a decision boundary.

Is there a free testosterone cutoff for low testosterone?

The EAU’s 2026 guideline says limited evidence supports 220 pmol/L, equal to 6.4 ng/dL or 64 pg/mL, in settings where free testosterone helps clarify the diagnosis. The Endocrine Society says no harmonized free-testosterone range exists. The test method still matters, so this number should not be placed on top of every lab’s free-testosterone range as if all assays were interchangeable.

What hematocrit level is too high on TRT?

The three guidelines compared here use 54% as an on-treatment management line, but their instructions are not identical. The Endocrine Society says to withhold therapy above 54% until hematocrit falls, then restart at a lower dose. The AUA says 54% or higher warrants intervention. The EAU says above 54% calls for adjustment or withdrawal and venesection when needed. A value below 54% can still need review.

What should estradiol be on TRT?

The AUA, Endocrine Society, and EAU do not publish one numeric estradiol treatment target for men on TRT. LabCorp’s sensitive LC-MS/MS test lists 8.0–35.0 pg/mL for adult men. Quest’s ultrasensitive LC/MS test lists 29 pg/mL or less. Those are lab reference intervals, not a shared guideline target.

Why are LabCorp and Quest testosterone ranges different?

Their tests, methods, reference data, and age groupings are not identical. LabCorp’s mass-spectrometry test lists 264–916 ng/dL. Quest’s mass-spectrometry test lists 250–1,100 ng/dL. Quest also has an adult-male immunoassay panel with a 250–827 ng/dL interval. The test code matters as much as the company name.

Is the LabCorp Free, Direct testosterone test the same as equilibrium dialysis?

No. LabCorp test 144980 uses a direct analog enzyme immunoassay. The Endocrine Society and EAU advise against direct free-testosterone immunoassays and favor equilibrium dialysis or a calculation based on total testosterone, SHBG, and albumin. Do not compare the raw values as if they came from the same test.

What PSA level stops TRT?

A PSA number does not diagnose cancer or create one universal stop rule. Before treatment, the Endocrine Society says not to start without urologic evaluation when PSA is above 4.0 ng/mL, or above 3.0 ng/mL in a man at higher prostate-cancer risk. During the first year, a confirmed rise greater than 1.4 ng/mL above baseline or a confirmed PSA above 4.0 ng/mL calls for urologic consultation.

When should I test testosterone after an injection?

For testosterone enanthate or cypionate, the Endocrine Society says to draw midway between injections. For long-acting injectable testosterone undecanoate, draw near the end of the dosing interval, just before the next injection. Record the product, dose, last-dose time, and blood-draw time with the result.

How often should labs be checked on TRT?

The schedule depends on the test, product, risk, and guideline. The Endocrine Society checks testosterone 3–6 months after treatment starts and hematocrit at baseline, 3–6 months, then yearly. The AUA calls for an initial testosterone check after an appropriate formulation-specific interval and then every 6–12 months when stable. The EAU checks testosterone and hematocrit at 3, 6, and 12 months, then yearly.

If my numbers are in range, is my dose right?

Not necessarily. “In range” means the result falls inside that laboratory’s interval for that test. It does not show that symptoms improved, that the draw was timed correctly, or that the result sits inside a treatment target. A total testosterone result of 1,000 ng/dL is unflagged on the Quest and ARUP 18–39 ranges in this ledger but above the AUA’s therapeutic range.

Can I compare two testosterone results from different labs?

You can compare them only with the method, test code, units, reference interval, draw time, and dose timing beside each result. A trend is easiest to read when the same laboratory and assay are used. Free-testosterone results from unlike methods should not be treated as the same ruler.

Do these ranges apply to women or transgender patients?

No. This ledger is limited to the adult-male ranges and male-hypogonadism guidance named on the page. It does not publish reference ranges or treatment targets for women or transgender patients.

How to cite this page

This is a neutral attribution record for the page and its dataset.

About this page

TRT Provider Guide’s editorial team compiled this page by reading the laboratory documents, guideline text, and original study listed below, then recording each number with its source. The page is educational, not medical advice, and it has not been clinically reviewed. Read personal results with the clinician who ordered them.

Primary sources

Guidelines and current statements

  1. Endocrine Society clinical practice guideline: Testosterone Therapy in Men With Hypogonadism (2018)
  2. Endocrine Society: Statement on Testosterone Replacement Therapy (July 16, 2026)
  3. American Urological Association: Testosterone Deficiency Guideline
  4. European Association of Urology: Male Hypogonadism chapter
  5. European Association of Urology: 2026 summary of changes

Original reference-range study

  1. Travison TG, Vesper HW, Orwoll E, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. JCEM. 2017;102(4):1161–1173.

Laboratory directories and interval documents

  1. Mayo Clinic Laboratories: TGRP, Testosterone, Total and Free, Serum
  2. Quest Diagnostics: Testosterone, Total, MS, test 15983
  3. Quest Diagnostics: Testosterone, Free, Bioavailable and Total, Males, test 30741
  4. Quest Diagnostics: Testosterone, Free (Dialysis) and Total, MS, test 36170
  5. Quest Diagnostics: Estradiol, Ultrasensitive, LC/MS, test 30289
  6. Quest Diagnostics: FSH and LH, test 7137
  7. Quest Diagnostics: Hypogonadism and Low Testosterone in Men, laboratory guide
  8. Quest Diagnostics: adult male hemoglobin and hematocrit interval notice
  9. LabCorp: Testosterone, Total, test 004226
  10. LabCorp: Testosterone, Total, Serum, Mass Spectrometry, test 500159
  11. LabCorp: Testosterone, Free, Direct, test 144980
  12. LabCorp: Sex Hormone-binding Globulin, test 082016
  13. LabCorp: Estradiol, Sensitive, LC/MS, test 140244
  14. LabCorp: Luteinizing Hormone, test 004283
  15. LabCorp: Follicle-stimulating Hormone, test 004309
  16. LabCorp: Prolactin, test 004465
  17. LabCorp: Prostate-specific Antigen, test 010322
  18. LabCorp: critical values and adult reference intervals, May 2025
  19. ARUP Laboratories: Testosterone, Free and Total, Includes SHBG, test 0070109
  20. ARUP Laboratories: Testosterone, Free by Equilibrium Dialysis with Total Testosterone by Mass Spectrometry, test 2004246